11/15/2021 8:09:44 AM
NeuroBo Pharmaceuticals Q3 Net Loss $3.5 Mln Or $0.16/shr Vs. Net Loss $3.1 Mln Or $0.19/shr Last Year
11/4/2021 8:11:08 AM
NeuroBo Pharmaceuticals Names Gil Price President And CEO
10/13/2021 8:10:32 AM
NeuroBo : Positive Recommendation From DMC Of Phase 2/3 Trial Of ANA001 In Hospitalized Patients With Severe COVID-19
10/1/2021 8:06:44 AM
NeuroBo Pharma Agrees With Institutional Investors For Sale In Registered Direct Offering Of 4.31 Mln Shares At $3.25
8/16/2021 8:11:44 AM
NeuroBo Pharma Q2 Net Loss $3.9 Mln Or $0.18/shr Vs. Loss $2.4 Mln Or $0.15/shr Prior Year
7/12/2021 8:36:38 AM
NeuroBo Pharma Shareholders Elect Hyung Heon Kim And Andrew Koven To Board
3/24/2021 8:08:17 AM
NeuroBo Pharma Receives Approval For Amendment Of Contingent Value Rights For Gemcabene
1/6/2021 8:33:39 AM
NeuroBo Pharma Acquires ANA Therapeutics For Late-Stage Oral Antiviral Development Program
8/11/2020 3:02:46 PM
NeuroBo Pharmaceuticals Q2 Loss/share $0.15 Vs. Loss $0.37 Year Ago
5/26/2020 8:39:53 AM
NeuroBo Pharma Gets Written Communication From FDA That Gemcabene Remains On Partial Clinical Hold
4/21/2020 8:32:48 AM
NeuroBo Pharma Announces Issuance Of U.S. Patent, Providing Broad Coverage Of NB-02 For Neurodegenerative Disorders